Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder. Here, we show that the CD63 antigen, which is located on the surface of extracellular vesicles (EVs), is associated with increased levels of muscle-abundant miRNAs, namely myomiRs miR-1, miR-133a, and miR-206, in the sera of DMD patients and mdx mice. Furthermore, the release of EVs from the murine myoblast C2C12 cell line was found to be modulated by intracellular ceramide levels in a Ca2+-dependent manner. Next, to investigate the effects of EVs on cell survival, C2C12 myoblasts and myotubes were cultured with EVs from the sera of mdx mice or C2C12 cells overexpressing myomiRs in presence of cellular stresses. Both the exposure of C2C12 myoblasts and myotubes to EVs from the serum of mdx mice, and the overexpression of miR-133a in C2C12 cells in presence of cellular stress resulted in a significant decrease in cell death. Finally, to assess whether miRNAs regulate skeletal muscle regeneration in vivo, we intraperitoneally injected GW4869 (an inhibitor of exosome secretion) into mdx mice for 5 and 10 days. Levels of miRNAs and creatine kinase in the serum of GW4869-treated mdx mice were significantly downregulated compared with those of controls. The tibialis anterior muscles of the GW4869-treated mdx mice showed a robust decrease in Evans blue dye uptake. Collectively, these results indicate that EVs and myomiRs might protect the skeletal muscle of mdx mice from degeneration.
Citation: Matsuzaka Y, Tanihata J, Komaki H, Ishiyama A, Oya Y, Rüegg U, et al. (2016) Characterization and Functional Analysis of Extracellular Vesicles and Muscle-Abundant miRNAs (miR-1, miR-133a, and miR-206) in C2C12 Myocytes and mdx Mice. PLoS ONE 11(12): e0167811. https://doi.org/10.1371/journal.pone.0167811
Editor: Diego Fraidenraich, Rutgers University Newark, UNITED STATES
Received: June 15, 2016; Accepted: November 21, 2016; Published: December 15, 2016
Copyright: © 2016 Matsuzaka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information file.
Funding: Intramural Research Grant (25-5) for Neurological and Psychiatric Disorders of NCNP.
Competing interests: The authors have declared that no competing interests exist.
Duchenne muscular dystrophy (DMD; OMIM #310200) is an X-linked recessive, severe and progressive muscle disease with a prevalence of 1 in 3,500 live male births, and is caused by mutations in the dystrophin gene [1,2]. This disorder is usually first recognized by muscular weakness from two to five years of age. Subsequently, patients lose their ability to ambulate before 12 years of age, and eventually experience failure of respiratory and cardiac functions owing to degeneration of the diaphragm and cardiac muscles . Serum creatine kinase (CK), which reflects the level of muscle damage, is commonly used as a diagnostic marker for DMD. However, false-positive or false-negative results are commonly observed, because CK release is increased by various factors, such as vigorous exercise , and is decreased by disease progression with age following the loss of muscle tissue , rendering quantitative diagnosis and prognostic applications of CK difficult. Thus, reliable biomarkers of DMD have been anticipated.
miRNAs are non-coding single stranded RNAs containing approximately 21 to 24 nucleotides, which regulate gene expression by base-pairing of their nucleotides 2 to 8 with the 5′- or 3′-untranslated regions of target mRNAs, primarily in the cytoplasm [6–8]. As the activities of approximately 50% of all coding genes in mammals are predicted to be regulated by miRNAs, the dysregulation of their expressions is associated with the pathophysiological conditions of many disorders. Some miRNAs are encapsulated into microvesicles, exosomes, or apoptotic bodies, whereas other miRNAs form complexes with RNA-binding proteins [9–16]. They can be internalized by recipient cells via extracellular vesicles (EVs), leading to the intercellular communication [13–18]. Despite the high levels of RNase activity within the circulating blood, because miRNAs are protected from RNase by their association with RNA-binding protein(s) or their inclusion within EVs, remarkably stable miRNAs were shown to be secreted into the extracellular space in non-vesicular or vesicular-encapsulated forms [19–21]. Several groups, including our own, previously reported that three myomiRs, namely, miR-1, miR-133a, and miR-206, were increased in the sera of animal models of muscular dystrophy as well as in patients [22–24]. This upregulation in myomiR levels is not limited to DMD patients, as increased levels of miR-1 were found in the sera of Becker muscular dystrophy (BMD), facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy patients, and increased levels of miR-133a and miR-206 were found in BMD patients . In addition, myomiR levels were shown to be inversely correlated with disease severity in DMD patients aged three to six years .
The increased levels of myomiRs in the sera of mdx mice have been demonstrated to be increased to near wild-type levels by restoration of the dystrophin protein using exon-skipping therapies . On the other hand, in the muscle of mdx mice, miR-1 and miR-133a levels have been shown to be downregulated, whereas miR-206 levels are upregulated [26, 27]. The expression of miR-1 and miR-133a in skeletal muscle can be restored by rescue of the dystrophin protein using exon-skipping techniques [27, 28]. These myomiRs have multiple roles in muscle development and regeneration, such as the regulation of genes involved in myogenesis, proliferation, and muscle fiber-type conversion [29, 30]. Thus, miRNAs have been acknowledged not only as noninvasive biomarkers of DMD, but also as therapeutic targets for many disorders. However, the potential involvement of these muscle-abundant miRNAs in the pathogenesis of DMD remains unclear. Elucidating the pathways regulating the release of myomiRs will be valuable towards gaining a better understanding of DMD pathogenesis and new targets for therapies. In fact, the release of miRNAs into intracellular and extracellular spaces was shown to be controlled by the neutral sphingomyelinase 2/ sphingomyelin phosphodiesterase 3 (nSMase2/SMPD3)-regulated secretory machinery of exosomes, which are membrane microvesicles about 30–100 nm in size generated from multivesicular bodies (MVBs) of the terminal endosomal pathway via the biogenesis of ceramide from sphingomyelin [31–35]. However, the mechanisms regulating the functions of myomiRs transported via EVs, including exosomes or larger vesicles, in the pathogenesis of mdx mice remain largely unknown. In the present study, we show that the release of EVs from C2C12 cells is regulated by ceramide metabolism in an intracellular Ca2+ concentration-dependent manner. The transport of miR-133a via EVs regulates the viability of C2C12 cells under conditions of cellular stress. In addition, the inhibition of ceramide synthesis by GW4869 (an inhibitor of exosome secretion), leading to the suppression of EV secretion, reduces muscle degeneration in mdx mice. Our findings demonstrate the potential of myomiRs as a novel noninvasive biomarker and the regulation of myomiR levels as a new therapeutic strategy for DMD.
Materials and Methods
Antibodies and reagents
Primary antibodies against mouse CD63 (3H1626), rabbit apolipoprotein A-I (apoA-I) (FL-267), and rabbit CD81 (H-121), and the anti-rat IgG- Horseradish peroxidase (HRP) secondary antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse primary antibody against MHC class II (M5/114.15.2) was purchased from Novus Biologicals (Littleton, CO). Rabbit primary antibody against caveolin-3 was synthesized by Eurofins Genomics K.K. (Tokyo, Japan). Rabbit primary antibody against flotillin-1 was purchased from Bioss USA (Woburn, MA), and the anti-mouse IgG (H+L) HRP secondary antibody was purchased from Bio-Rad Laboratories, Inc. (Berkeley, CA). Anti-rabbit IgG HRP-linked secondary antibody was purchased from Cell Signaling Technology, Inc. (Beverly, MA). Anti-LAMP2 (M3/84) and anti-GAPDH (EPR6256) antibodies were purchased from Abcam (Cambridge, UK). Mouse monoclonal antibody against CD9 (IVA50) was purchased from Abnova (Taipei City, Taiwan). Mouse monoclonal antibody against calnexin (4F10) was purchased from MBL Laboratories CO., LTD (Nagoya, Japan). Mouse monoclonal antibody against HSP90 (H9010) was purchased from StressMarq Biosciences Inc. (Victoria, Canada). Actinomycin D was purchased from Focus Biomolecules (Plymouth Meeting, PA). Methyl-ß-cyclodextrin, 2-aminoethyl diphenylborinate (2-APB), A23187, C6-ceramide, and monensin sodium salt were purchased from Sigma-Aldrich (St. Louis, MO). BAPTA-acetoxymethyl ester and EGTA-acetoxymethyl ester were purchased from DOJINDO Laboratories (Kumamoto, Japan). C2-ceramide and simvastatin were purchased from Focus Biomolecules. Anhydrous caffeine was purchased from Nacalai Tesque (Kyoto, Japan). Cyclopiazonic acid, D-erythro-MAPP, ebselen, nocodazole, and U-0126 were purchased from Cayman Chemical Company (Ann Arbor, MI). GW4869 was purchased from Calbiochem (San Diego, California). Sphingosine-1-phosphate (S1P) was purchased from LKT Laboratories, Inc. (St Paul, MN).
Five unrelated Japanese patients with DMD and four healthy controls were enrolled in this study with the approval of the Ethics Committee of the National Center of Neurology and Psychiatry (approval ID: A2011-113), which followed regulation of Helsinki Declaration. All results are treated with standard medical confidentiality and confidential to the extent allowed by law. Written informed consent was obtained from all participants after explaining the details of the study, prior to the collection of peripheral blood.
All animals used in this study were housed in a specific pathogen free facility of the National Center of Neurology and Psychiatry and treated in accordance with the guidelines provided by the Ethics Committee for the Treatment of Laboratory Animals of the National Center of Neurology and Psychiatry (approval ID: 2013007), which has adopted the three fundamental principles of replacement, reduction, and refinement. Connsistent with the approvals stipulated by the protocol, all efforts were made to minimize suffering or discomfort to the animals. mdx mice with C57BL/6 background, transgenic mdx mice overexpressed dystrophin gene which lack coding region from exon 45 to exon 55 by CAG promoter with C57BL/6 background (Tanihata J. et al. in preparation of manuscript), and age-matched wild-type C57BL/6 male control mice were used in this study.
Two μg of antibodies were mixed with 0.1 mL of sera, and incubated at 4°C overnight. Protein G Sepharose® (100 μL; Sigma-Aldrich) was added to the sera, mixed well, and then incubated at 4°C for 60 min. The immunoprecipitated complexes were collected by centrifugation at 3,000 × g for 2 min at 4°C, and the supernatant was discarded. The pellet was washed with 1 mL of phosphate-buffered saline (PBS). The centrifugation and washing steps were repeated at least 3 times. The pellet was then resuspended in 100 μL of 5% sodium dodecyl sulphate (SDS) solution, heated at 95°C for 5 min, and centrifuged for 1 min at 12,000 × g at room temperature, and then the supernatant was collected as the immunoprecipitated samples.
Extraction and quantification of miRNA
Total RNA was extracted from 0.1 μL of serum using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA) as 25 μL of RNA eluate according to the manufacturer’s protocol. RNA eluate (4.5 μL) was reverse transcribed using the TaqMan miRNA Reverse Transcription kit (ABI, Foster City, CA) and miRNA-specific stem-loop primers (part of the TaqMan miRNA assay kit, ABI) as previously described (21). The expression levels of miRNA were quantified by real-time PCR using individual miRNA-specific primers (part of TaqMan miRNA assay kit, ABI) with StepOne™ Real-Time PCR System (ABI) according to the manufacturer’s protocol. Samples were subjected to real-time PCR in triplicate. The expression of each miRNA was represented as relative values normalized by the expression of miR-16 and cel-miR-39 used as an internal control and spike-in miRNA, respectively. Data analysis was performed by SDS 2.1 real-time PCR data analysis software (ABI). Expression data are shown as median values obtained from three samples together with the standard deviation.
Purification and quantitation of EVs
Serum was harvested from the peripheral blood of DMD patients in tubes by centrifugation at 3,000 × g for 15 min. Isolation of exosomes from serum was performed by Total Exosome Isolation reagent (Invitrogen) or ExoQuick-LP™ (System Bioscience, Palo Alto, CA), according to the manufacturer’s protocol. Briefly, 50 μL of Total Exosome Isolation solution or 63 μL of ExoQuick solution were added to 250 μL of serum. The mixture was vortexed for 15 seconds and then incubated at 4°C for 30 min. After centrifugation at 10,000 × g for 10 min at room temperature, the supernatant was discarded. The centrifugation and aspiration steps were repeated. The pellet containing the EVs was resuspended in 1× PBS. EVs were also isolated from C2C12 cells, which were conditioned in serum-free media for 24 hr at 90% confluence. Media were harvested, and then centrifuged at 2000 × g for 30 min to remove cells and debris. EVs were then isolated using Total Exosome Isolation reagent (Invitrogen). Briefly, the Total Exosome Isolation reagent (1/5 voulume) was added to cell-free culture media. The solution was vortexed for 15 seconds, and then incubated at 4°C overnight. After centrifugation at 10,000 × g for 1 hour at 4°C, the supernatant was discarded. Again, the centrifugation and aspiration steps were repeated. The pellet containing the EVs was resuspended in 1 × PBS and then filtered through a 0.22 μm filter, Millex-GV (Millipore Corporation, Billerica, MA). The EVs were confirmed using antibodies against exosomal marker proteins as well as flow cytometry. Briefly, recovered exosomes were incubated with 4-μm diameter aldehyde/sulfate latex beads, 4% w/v, (Thermo Fisher Scientific, Waltham, MA) for 15 min at room temperature. The mixture was then mixed in a final volume of 200 μL of PBS at room temperature under gentle agitation. Two hours later, the reaction was terminated by the addition of 100mM glycine for 30 min at room temperature. After centrifugation, the pellet was washed in PBS containing 0.5% of bovine serum albumin and then incubated with specific antibodies. Beads were analyzed by flow cytometry using a BD Biosciences FACSCalibur using FACSDiva version 6.0 software. Concentrations of the EVs were then determined indirectly by quantifying protein concentrations. The amount of released EVs was quantified by measuring the activity of acetylcholinesterase (AChE) (Sigma-Aldrich), as previously described . The total amount of EVs isolated from the culture media was suspended in 800 uL of PBS, and 100 μL of 12.5 mM acetylthiocholine and 100 μL of 1 mM 5,5’-dithio-bis (2-nitrobenzonic acid) (Sigma-Aldrich) was added in a final volume of 1 mL, and then the mixture was incubated at 37°C for 30 min. The EV solution (300 μL each) was divided into 96-well plates in triplicate and then absorbance at 415 nm was measured on a 680 microplate reader (Bio-Rad Laboratories, Inc.).
Dot blot analysis
Ten μg/μL of EVs extracted from mouse serum was serially diluted in PBS. One μL of the EV solution was dotted onto an Immobilon-P transfer membrane, which is a microporous polyvinylidene fluoride membrane (Millipore Corporation, Billerica, MA). The membrane was dried at 60°C for 10 minutes, and then incubated with primary antibodies (2 ug) at 4°C overnight, and then with HRP-conjugated secondary antibodies at room temperature for 1 hr. Chemiluminescence was detected using ECL Prime Detection Reagent (GE Healthcare, Buckinghamshire, UK) and analyzed using LAS-3000 (Fujifilm Corporation, Tokyo, Japan).
Western blotting analysis
For Western blotting analysis, 50 μL of sera from mdx and wild-type (wt) mice were resolved by 12% SDS PAGE, and then transferred onto a Polyvinylidene Difluoride (PVDF) membrane (Merck Millipore, Billerica, MA). An anti-LAMP2 antibody (1:1,000 in a mixture of tris-buffered saline (TBS) and Polysorbate 20 (TBST)) and an anti-rat IgG-HRP antibody (1:1,000 in TBST) were used as first and secondary antibodies, respectively. Signal detection was performed using antibodies coupled to HRP and ECL Prime Detection Reagent (GE Healthcare, Buckinghamshire, UK), together with analysis by LAS-3000 (Fujifilm Corporation).
Creatine kinase activity
Serum CK levels were measured using the Fuji Dri-Chem system (Fujifilm Medical Co. Ltd., Tokyo, Japan) according to the manufacturer’s protocol. Serum (10 μL) was deposited on a Fuji Dri-Chem slide and incubated at 37°C. The increase in absorbance by the generated dye was measured spectrophotometrically for 5 min at 540 nm and the activity was calculated according to the installed formula. Data were expressed as units per liter (U/L).
Cell viability analysis
C2C12 murine myoblast cells were cultured in Dulbecco's Modified Eagle's medium (DMEM; Sigma-Aldrich) with 10% (v/v) fetal bovine serum (Cell Culture Technologies, Lugano, Switzerland) and 1% (v/v) penicillin/streptomycin (Wako Pure Chemical Industries Ltd., Osaka, Japan) as the growth medium. The cells were grown at 37°C in controlled humidified air with 5% CO2. For myogenic differentiation of myoblasts into myotubes, the growth medium was changed to differentiation medium, namely, DMEM containing 2% heat-inactivated horse serum and 1% penicillin/streptomycin. Briefly, C2C12 cells were grown in 96-well plates (BM Equipment Co. Ltd., Tokyo, Japan) in growth medium until confluent and then changed to serum-free medium (DMEM containing 1% penicillin/streptomycin) and incubated with or without inducers or suppressors of EV secretion for the indicated times. The number of cells was determined by measuring the absorbance at 450 nm of the formazan product in the culture medium using a 680 microplate reader after incubation with 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8) from Cell Counting Kit-8 (CCK-8) (DOJINDO Laboratories).
Three DNA fragments, namely, precursors of miR-1a, miR-133a, and miR-206 (pre-miR-1a, pre-miR-133a, and pre-miR-206) were synthesized (Bioneer, Alameda, CA), and inserted into the intron site of the pEM-157 vector, which contains the cytomegalovirus promoter driving transcription of the dsRed-fluorescent protein-coding sequence interrupted by an intron. The sequences of the three fragments were as follows: pre-miR-1a: 5′-GTTTAAACCCAGGCCACATGCTTCTTTATATCCTCATAGATATCTCAGCACTATGGAATGTAAGGAAGTGTGTGGTTTTGGACTAGT-3′, pre-miR-133a: 5′-GTTTAAACAGAAGCCAAATGCTTTGCTGAAGCTGGTAAAATGGAACCAAATCAGCTGTTGGATGGATTTGGTCCCCTTCAACCAGCTGTAGCTGCGCATTGATCACGCCGCAACTAGT-3′, pre-miR-206: 5′-GTTTAAACGCTTGGGACACATACTTCTTTATATGCCCATATGAACCTGCTAAGCTATGGAATGTAAAGAAGTATGTATTTCAGGCACTAGT-3′. C2C12 cells cultured in 24-well dishes were transfected with these plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Briefly, 0.2 μg of each plasmid was diluted in 25 μL of Opti-MEM®I Reduced Serum Medium (Invitrogen). The plasmid solutions were mixed with 4 μL of PLUS™ Reagent (Invitrogen), and then incubated at room temperature for 15 min. After incubation, the plasmid solutions were mixed with 25 μL of Lipofectamine 2000, diluted 25 times by Opti-MEM® I Reduced Serum Medum, and then incubated at room temperature for 15 min. The plasmid solutions were added to C2C12 cells in serum-free medium. After incubation at 37°C for 3 hrs, the medium was changed to growth medium, and then incubated at 37°C for the indicated times.
C2C12 myoblast cells were cultured to confluence in growth medium in 6-well plates, and then the growth medium was changed to serum-free medium (DMEM containing 1% penicillin/streptomycin with 0.5 mM of H2O2). The cells were incubated with or without EVs (4 μg) for 24 hours. Then, caspase-3 activity was quantified using the Caspase-3/CPP32 Colorimetric Assay Kit (BioVision Inc., Milpitas, CA). Briefly, cells were harvested, and the supernatant was removed by centrifugation. Pellets were suspended in 50 μL of chilled cell lysis buffer, and then incubated on ice for 10 min, and centrifuged for 1 min at 10,000 × g. Supernatants were transferred to fresh tubes, and protein concentrations were measured. Protein solutions were adjusted to a concentration of 100 μg/μL by dilution with PBS. Fifty μL of 2 × Reaction Buffer and 5 μL of 4 mM DEVD-pNA substrate were added to 50 μL of the protein solutions and then incubated at 37°C for 2 hrs. Caspase-3 activity was determined by measuring the absorbance at 405 nm using a 680 microplate reader.
Analysis of skeletal muscle regeneration of mdx mice
GW4869 was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1.5 mM, and then 2.5 μL of 5% methane sulfonic acid solution was added to 50 μL of the GW4869 solution, resulting in a final concentration of 1.43 mM of GW4869. The solution was then incubated at 37°C until the color of the solution became clear, and the GW4869 solution was further diluted to 100 μM in PBS. One-hundred μL of this final GW4869 solution was intraperitoneally injected into mdx mice. After 5 or 10 days, whole body blood was collected from the abdominal aorta. Twenty-four hours before sacrifice, mice were injected intraperitoneally with 1% evans blue dye (EBD; Nacalai Tesque) in PBS as described previously . Muscles were harvested, frozen in melting isopentane, and sectioned. The muscle sections were incubated in ice-cold acetone for 10 min, washed three times for 10 min with PBS, and mounted with Vectashield mounting medium. The presence of EBD in myofibers was analyzed by fluorescence microscopy.
Secondary structure of myomiRs
GC contents and ΔG were estimated using by a web tool, which is available free of charge at https://sg.idtdna.com/calc/analyzer.
Expression levels of myomiRs and EV contents in sera of mdx mice and DMD patients
We previously showed that myomiRs in the serum of mice were upregulated by cardiotoxin-induced muscle injury . It has also been reported that miR-1 and miR-133a levels are downregulated in dystrophic muscle and recover to normal levels by the rescue of dystrophin expression [26, 27]. To elucidate whether myomiR levels in the serum are positively associated with muscle degeneration, the levels of three myomiRs, namely, miR-1, miR-133a, and miR-206, in the sera of transgenic (tg) mdx mice, overexpressing a truncated dystrophin transcript with a deletion from exon 45 to 55, mdx mice, and wild-type (wt) mice were quantified by qRT-PCR. Consistent with a previous report , the levels of myomiRs in the serum of mdx mice were upregulated compared with those of wt mice, but the tg mice showed a decreased level compared with that of mdx mice (S1A Fig). Ubiquitously expressed miR-21, mir-29, and small nucleolar RNA 202 (sno202) were used as positive controls, and did not show any significant differences between wt, mdx and tg serum, whereas miR-302, which specifically expressed in embryonic stem cell, did not detect in all of sera (S1A Fig). In addition, we previously showed that the levels of myomiRs in EVs and EV-depleted supernatant fractions from the sera of DMD patients were significantly increased compared with that of healthy controls . To determine the levels of the three myomiRs in the two fractions from the sera of tg, mdx, and wt mice, sera were separated by centrifugation followed by miRNA extraction. qRT-PCR demonstrated that the levels of the three myomiRs in these fractions were significantly downregulated in tg mice compared with mdx mice, in which the expression levels of the three myomiRs were significantly increased compared with wt mice (Fig 1A). To analyze the contents of the EVs in the sera of tg, mdx, and wt mice, EVs were isolated from the sera by centrifugation, and then quantified by AChE activity and EV markers. The amount of EVs, which was verified by exosomal marker proteins (S2A Fig), in the sera of mdx and tg mice at 7 weeks of age was significantly increased compared with that of wt mice; however, at 13 and 27 weeks of age, there were no significant differences in the amount of EVs between the mice (Fig 1B, left, S2B and S2C Fig). In addition, DMD patients demonstrated significantly greater amounts of EVs compared with healthy controls (Fig 1B, right). Furthermore, to characterize EV markers associated with increases in these miRNA levels, we performed immunoprecipitation assays using five antibodies and EVs from the sera of DMD patients and healthy controls. Levels of three miRNAs (miR-1, miR-133a, and miR-206 levels) and of two miRNAs (miR-1 and miR-133a) were found to be significantly enriched in CD63- and MHC II-associated EVs, respectively, in the serum of DMD patients compared with that of healthy controls (Fig 1C–1E). miR-16 were used as ubiquitous-expressed marker (S3A Fig). Similarly, to identify EV markers in mice, immunoprecipitation was performed using the five antibodies and sera from wt, mdx, and tg mice. The levels of the three myomiRs were significantly increased in CD63-associated EVs of mdx mice compared with wt mice, whereas the levels in tg mice were significantly decreased compared with mdx mice (S3B Fig). Furthermore, levels of miR-133a and miR-206 were significantly increased in EVs associated with CD81, flotillin-1, and MHC II, and flotillin-1 and MHC II, respectively, in mdx mice compared with wt mice (S3B Fig). In addition, miR-128, which expressed specifically in brain, did not detecte in EVs associated with caveolin-3 in wt mice, although miR-128 in other all of EVs were detected (S3B Fig). Ubiquitously expressed miR-16, miR-21, and miR-212 were used as positive controls, and did not show any significant differences between wt, mdx and tg serum, whereas miR-122a and miR-323 which expressed specifically in liver and brain, respectively, and miR-302 did not dectect in all of EVs (S3B Fig). These results suggest that an increase in the levels of myomiRs in EVs may be associated with muscle degeneration.
(A) Levels of miR-1, miR-133a, and miR-206 in EVs-containing and EV-depleted supernatants, separated from the sera of wt, mdx, and tg mice (7-weeks old, n = 3, 4, and 4, respectively). Data are represented as means + S.E. *: P < 0.05, **: P < 0.01 for mdx vs wt or mdx vs tg. (B) EVs were extracted and quantified by AChE activity from the sera of wt, mdx, and tg mice at 7, 13, and 27 weeks of age (n = 3, 4, and 4, respectively, *: P < 0.05, **: P < 0.01 vs wt) (left) and DMD patients and healthy controls (right), (n = 5 and 4, respectively, *: P < 0.05). (C-E) miR-1 (C), miR-133a (D), and miR-206 (E) levels in EVs separated by immunoprecipitation with anti-caveolin-3 (cav3), anti-CD63, anti-CD81, anti-flotillin-1 (flot1), or anti-MHC class II (MHC II) antibodies in the sera of DMD patients and controls (n = 5 and 4, respectively). *: P < 0.05 vs controls.
Ceramide metabolic pathways control EV secretion from C2C12 cells by intracellular calcium-dependent mechanisms
Growing lines of evidence have indicated that exosome secretion is regulated by the ceramide synthesizing enzymes nSMase2/Smpd3 or the ceramide-related metabolite, Sphingosine-1-phosphate (S1P) [32, 38]. To assess whether ceramide and S1P control EV secretion in C2C12 myoblast cells, EVs, confirmed with exosomal protein markers by flow cytometry (S4A Fig) and western blot (S4B Fig), were extracted from the medium of C2C12 cells cultured with or without the nSMase inhibitor GW4869, and quantified by AChE activity. EV content was significantly decreased by treatment with GW4869 (8 μM) treatment (Fig 2A, P < 0.01). In contrast, treatment with C2- or C6-ceramides significantly increased EV release from C2C12 myoblast cells (Fig 2B–2D), and mitigated the inhibitory effect of EV release by GW4869 (Fig 2C and 2D, P < 0.001 and P < 0.001, respectively). Moreover, ebselen, which acts as a glutathione peroxidase mimic, significantly reduced the amount of EVs released from C2C12 myoblast cells (Fig 2E, P < 0.001). On the other hand, the ceramidase inhibitor d-erythro-MAPP (60 μM), significantly increased EV release (Fig 2F, P < 0.001). Furthermore, S1P (40 uM) significantly increased the release of EVs from C2C12 myoblast cells (Fig 2G, P < 0.001), and ameliorated the inhibitory effect of GW4869 (Fig 2G, P < 0.001). These findings taken together suggested that EV release from C2C12 myoblast cells can be regulated by ceramide metabolism (Fig 2H).
C2C12 cells were cultured in growth medium until confluent, and then incubated with serum-depleted medium with or without GW4869 for 72 hr (A), C6-ceramide for 24 hr (B), GW4869 and C6-ceramide (C) or GW4869 and C2-ceramide (D) for 72 hr, ebselen for 48 hr (E), D-erythro-MAPP (deMAPP) for 2 hr (F), and GW4869 or S1P for 48 hr (G). The EVs from these cells were extracted from the culture medium, and the amounts of the released EVs were quantified by measuring AChE activity. Data are represented as means + S.E. of absorbance at 405 nm. *: P < 0.05, **: P < 0.01, ***: P < 0.001. (H) Schematic figure of ceramide biogenesis and metabolism. H2O2: hydrogen peroxide; S1PR1/3: S1P receptor 1 or 3; Gαi: a subunit of G protein.
Furthermore, exosome release in some cell types is also known to be regulated by a calcium-dependent mechanism [39–41]. We therefore hypothesized that intracellular calcium also regulates EV secretion in C2C12 myoblast cells. To test this hypothesis, EVs released from C2C12 myoblast cells incubated with or without the calcium ionophores monensin and A23187 were quantified by AChE activity. These two calcium ionophores significantly ameliorated the inhibitory effect of GW4869 on EV release from C2C12 cells (S5A and S5B Fig, P < 0.001, P < 0.01, respectively). Furthermore, a decrease in EV release by GW4869 was restored by caffeine, a ryanodine receptor activator (S5C Fig). However, the increase in EV release from C2C12 myoblast cells by d-erythro-MAPP was significantly recovered in the presence of the calcium-chelating agents BAPTA and EGTA (S5D and S5E Fig), or 2-APB, an inhibitor of the inositol 1,4,5-trisphosphate, the InsP3 receptor, and transient receptor potential channels (S5F Fig, P < 0.001). Furthermore, increases in EV release by S1P were significantly decreased in the presence of EGTA (S5G Fig, P < 0.001). Loperamide, a calcium release-activated channel activator, and cyclopiazonic acid, a sarcoendoplasmic reticulum calcium transport ATPase inhibitor, significantly increased EV release from C2C12 myoblast cells (S5H and S5I Fig, P < 0.001 for each). Taken together, these results indicate that EV release is regulated by intracellular calcium-dependent mechanisms in C2C12 myoblast cells (S5J Fig).
Effects of EVs on C2C12 cell survival
Exosomes released from myotubes have been reported to regulate myoblast proliferation and differentiation through intercellular crosstalk [42, 43]. However, the roles of EVs in the muscle degeneration of DMD patients remains to be clarified. To address this issue, C2C12 cells were incubated in serum-depleted medium with a low (0.7 μg), medium (2 μg), or high (7 μg) concentration of EVs extracted from the serum of mdx mice. The survival of myoblasts incubated for 24 hr with a high or medium concentration of EVs extracted from the serum was significantly increased compared with cells incubated without EVs (Fig 3A left, P < 0.001, respectively). In addition, the number of myotube cells incubated with a high concentration of EVs for 48 and 72 hrs was significantly increased compared with cells incubated without EVs (Fig 3A right, P < 0.001 and P < 0.05, respectively). Furthermore, the survival of myoblast cells incubated with a medium or high concentration of EVs extracted from C2C12 culture medium for 24 hrs was significantly increased compared with that without EVs (S6A Fig left, P < 0.05 and P < 0.001, respectively). Significant increases in the survival of myotube cells were observed upon incubation with a high concentration of EVs extracted from C2C12 culture medium for 48 or 72 hrs (S6A Fig right, P < 0.001 and P < 0.05, respectively). Furthermore, to determine whether EVs regulate the survival of C2C12 cells in response to apoptosis-associated stress, myoblasts were incubated with EVs from the serum of mice (Fig 3B and 3C) in one of three types of media; with H2O2, with ethanol, or with actinomycin D. In myoblasts and myotubes, the survival of cells incubated with a high concentration of EVs from the serum of mice was significantly increased in the presence of H2O2 (Fig 3B and 3C). The uptake of EVs and the mobility of the internalized EVs were reduced by the membrane cholesterol depletion regent methyl-ß-cyclodextrin (MßCD), the microtube polymerization inhibitors, nocodazole and simvastatin, or the MAPK inhibitor U0126 . Increases in the survival of myotubes incubated with EVs from the serum of mice were significantly reversed by the treatment with MßCD, nocodazole, simvastatin, or U0126 (S6B–S6D Fig).
(A) C2C12 myoblasts (left) and myotubes (right) that were differentiated for 3 days were incubated for the indicated times in serum-depleted medium with low (0.7 μg), medium (2 μg), or high (6 μg) concentrations of EVs that were extracted from the serum of mdx mice. (B,C) C2C12 myoblasts (B) and myotubes (C) differentiated for 6 days were incubated with or without EVs (0.05 μg, 0.1 μg, 0.2 μg, 0.4 μg, 0.8 μg, or 1.6 μg) (B) or (0.7 μg, 2.0 μg, or 6.0 μg) (C) extracted from the serum of mice subjected for 24 hr to three different conditions; H2O2 (10 mM), ethanol (20%), or actinomycin D (0.5 mg/mL). Data represent mean + S.E. of absorbance at 450 nm of CCK-8. *: P < 0.05, **: P < 0.01, ***: P < 0.001. Each independent experiment was repeated at least 3 times.
Effect of myomiRs via EVs on the survival of C2C12 myoblasts and myotubes
Next, to analyze the effect of myomiRs via EVs on cell survival, we performed gain-of-function experiments of miR-1, miR-133a, and miR-206, which were upregulated within EVs during the differentiation of C2C12 cells (S7 Fig), using C2C12 cells and EVs extracted from C2C12 cells transfected with each miRNA (Fig 4A, S8 Fig). The survival of myoblasts incubated with EVs (6 μg) extracted from the culture medium of C2C12 cells transfected with miR-133a was significantly increased compared with those of cells transfected with miR-1 or miR-206, or untransfected cells in serum-depleted medium (S9A Fig, Pc < 0.05). In the presence of H2O2, the cell survival of myotubes incubated with EVs containing a large amount of miR-133a was significantly increased compared with cells incubated with EVs prepared from untransfected C2C12 cells (non-TF EVs) (S9B Fig, P < 0.05). All of the C2C12 myotubes cultured with EVs (7 μg) from cells transfected with miR1, miR-133a, or miR-206 demonstrated significantly increased survival compared with cells cultured without EVs in serum-depleted medium for 48 and 72 hr (Fig 4B, P < 0.001). Furthermore, we compared the survival of cells treated with two types of EVs, namely, EVs-133a and EVs-non-133a, which are EVs from C2C12 cells transfected with and without miR-133a, respectively. The cell survival of C2C12 myotubes cultured with EVs-133a from medium of C2C12 cells transfected with miR-133a, miR-1/miR-133a, miR-133a/miR-206, or miR-1/miR-133a/miR-206 were significantly increased compared with EVs-non-133a from cells transfected with miR-1, mir-206, miR-1/miR-206, or nontransfected cells in serum-depleted medium for 72 hours (Fig 4B, P < 0.01), but not for 24 and 48 hours (Fig 4B). No significant differences were observed in C2C12 myotubes cultured with EVs from cells transfected with miR-1, miR-206, miR-1/miR-206 compared with that from nontransfected cells (Fig 4B). Furthermore, the numbers of C2C12 myotubes cultured with low (0.8 μg) or medium (2.0 μg) concentrations of EVs were significantly increased compared with that without EVs for 72 hr (S10A and S10B Fig, P < 0.05 and P < 0.001, respectively). However, no significant differences were observed in the cell survival of C2C12 myoblasts cultured with EVs-133a or EVs-non-133a for 48 or 72 hrs (data not shown). These results suggest that the survival of myotubes may be partially regulated by miR-133a via EVs.
(A) Schematic representation of the experiment. C2C12 cells were cultured and transfected with miR-1, miR-133a, miR-206, miR-1/miR-133a, miR-1/miR-206, miR-133a/miR-206, or miR1/miR-133a/miR-206. Their EVs were extracted from the culture medium, and added to C2C12 cells in serum-depleted medium. (B) Myotubes differentiated for 4 days were incubated in serum-depleted medium with or without 7 μg of EVs extracted from the medium of C2C12 cells transfected with miR-1, miR-133a, miR-206, miR-1/miR-133a, miR-1/miR-206, miR-133a/miR-206, or miR-1/miR-133a/miR-206 for the indicated times. Data represent mean + S.E. **: Pc < 0.01, ***: Pc < 0.001.
Effect of miR-133a via EVs on the expression of genes associated with apoptosis and differentiation in C2C12 cells
We next investigated whether the effect miR-133a via EVs on the survival of myotubes was regulated by its target genes directly or indirectly through the targeting functions of miRNA. To test this hypothesis, we quantified the expression levels of putative target genes in C2C12 cells cultured with or without EVs containing a large amount of miR-133a. qRT-PCR demonstrated that the levels of miR-133a were significantly upregulated by the incubation of cells with the EVs (Fig 5A). Furthermore, the levels of bcl-2, caspase-9, myoG, and srf transcripts were significantly decreased by the incubation of cells with these EVs (Fig 5B, left). Whereas the expression level of myh1 was significantly upregulated by the incubation of cells with these EVs, cycd1 was not changed (Fig 5B, right). Moreover, caspase-3 activity in C2C12 cells cultured with EVs in the presence of H2O2 was significantly decreased compared with that without EVs (Fig 5C). These findings indicated that the protective effects against apoptosis of C2C12 cells by EVs might be in part controlled by regulation of the expression of genes targeted by miR-133a.
(A) Myotubes were incubated for 72 hr with 1.0 or 2.0 μg of EVs extracted from C2C12 cells. Total RNA was extracted from the myotubes. Levels of miR-133a (A) and relative mRNA levels of putative target genes (B) were measured by RT-quantitative PCR. (C) Caspase-3 activity was measured in lysates of C2C12 myotube cells cultured with EVs (4 μg) for 24 hr. Data represent mean + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001 versus the relevant control.
Inhibition of ceramide synthesis ameliorates muscular dystrophy in mdx mice
To further investigate whether myomiRs improve muscular dystrophy in mdx mice, GW4869 (100 μM) was intraperitoneally administered into mdx mice for 5 or 10 days (Fig 6A). After the administration of GW4869, the levels of miR-1, miR-133a, and miR-206, as well as the level of CK, which is indicative of sarcolemmal leakage, were quantified. The levels of myomiRs in the serum (Fig 6B), serum-derived EVs (S11A Fig), and the EV-depleted serum supernatant (S11B Fig) of mdx mice treated with GW4869 were significantly decreased compared with that of the controls. Furthermore, serum CK levels of mdx mice treated with GW4869 for 5 and 10 days were also significantly decreased compared with those of controls (Fig 6C, P < 0.05 and P < 0.01, respectively). The tibialis anterior muscle of GW4869-injected mdx mice showed a significant decrease in the area of uptake of EBD, which accumulates in damaged cells, compared with that of control mdx mice (Fig 6D, top and Fig 6E). On the other hand, only a slight, but insignificant decrease in EBD uptake was observed in the diaphragm of mdx mice injected with GW4869 compared with that of the controls (Fig 6D, bottom and Fig 6E). To test the improvement of myofiber structure and function upon GW4869 injection, we analyzed the expression of utrophin in the TA muscle of mdx mice treated with GW4869 for 10 days, as well as in untreated mdx mice. However, utrophin protein levels in GW4869-treated mice were not increased compared to those of controls (S12 Fig). These results suggested that the inhibition of ceramide synthesis leads to the suppression of EV secretion, which may affect the level of muscular dystrophy in mdx mice.
(A) Experimental timeline of GW4869 administration into mdx mice. Six-week old mdx mice were injected daily with 100 μL of GW4869 (100 μM) intraperitoneally for 5 or 10 days. After the GW4869 administration period, EBD was injected, and then the next day, whole body blood was collected from the abdominal aorta. miR-1, miR-133a, and miR-206 levels (B) and CK levels (C) in the serum were quantified by RT-quantitative PCR and the Fuji Dri-Chem system, respectively. (D) EBD uptake analyzed in TA muscle and diaphragm sections of mdx mice injected with or without GW4869. (E) Quantification of the area of EBD-positive muscle damage in TA muscles and diaphragms of mdx mice injected with or without GW4869. Data represent mean + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
The present study showed that myomiRs are noninvasive biomarkers for the diagnosis of DMD, and that the regulation of myomiR levels may possibly be established as a novel therapy for DMD. We found significant decreases in the levels of miR-1, miR-133a, and miR-206 in the serum of tg mice (mdx mice overexpressing a truncated dystrophin protein showing normal muscle activities) compared with those of mdx mice at 7 weeks of age. Moreover, Roberts et al. reported that restoration of the dystrophin protein by the skipping of exon 23 from the mature dystrophin transcript partially normalized serum myomiRs levels . Furthermore, we previously demonstrated that the upregulation of myomiRs levels in the sera of mice occurred transiently upon CTX-induced injury of their TA one day after the injury . These data suggested that an increase in serum myomiR levels might be dependent on muscle degeneration.
Next, we presented evidence that the secretion of EVs from C2C12 cells was regulated by sphingolipids metabolism. In agreement with a previous report , our study demonstrated significant increases in the secretion of EVs into the extracellular space in the sera of young DMD patients or mdx mice compared with controls. However, difference of serum myomiRs level in exosome and exosome-depleted supernatant fractions between our study and previously published data was observed . The two studies were differences for extraction method of exosomes and RNAs from mice serum, and its serum volume as the starting materials. It was reported the difference of number of extracellular vesicles extracted using by Total exosome isolation regent and ultracentrifugation method, although these particle size distributions isolated by the two methods showed no differences and exhibited similar size distribution for exosome, that is a mean diameter of 70–80 nm . Moreover, it was previously reported that the amount of total RNA recovered from exosomes using by Total exosome isolation regent, specifically the small RNA fraction, is higher compared with ultracentrifugation protocol, and the profiles of RNA recovered from exosomes by two different protocol were similar, that is majority of RNA content was < 200 nt . The miRNAs with low GC content or low initial total RNA concentration in the starting materials are recovered inefficiently using by TRIzol compared with mirVana miRNA isolation kit, because of effective isolation of miRNAs needs to base pair with other RNAs as carriers . The GC contents of three myomiRs were relatively low in spite of the unstable secondary structure of the myomiRs based on ΔG values (S1 Table, S13A–S13C Fig). Taken together, the difference of myomiRs level between our present study and published data might be observed. In addition, it was reported that the secretion of myomiRs from cultured C2C12 myotubes was increased by the addition of serum from DMD patients or the stimulation with fibroblast growth factors (FGF), transforming growth factor-β, or tumor necrosis factor-α (TNF-α) . Furthermore, nSMase2/Smpd3 is activated by TNF-α-stimulated p38 MAPK [49, 50], and preferentially traffics to the plasma membrane upon exposure to an oxidant, such as H2O2, and is inhibited by the antioxidant, glutathione-SH (GSH) [51, 52]. Thus, the release of EVs into the extracellular space in DMD patients might be induced by the activation of nSMase2/Smpd3, following ceramide production mainly from sphingomyelin in response to some types of cellular stimulation.
In this study, miR-133a in EVs exerted protective effects against C2C12 cell stress, via the suppression of the expression of apoptosis-associated genes, despite the EVs including various bioactive molecules, such as mRNA, protein, and DNA. It was reported that the overexpression of these myomiRs had little effect on the proliferation or apoptosis of cardiac progenitor cells (CPCs) under basal conditions, whereas miR-133a increased cell survival under oxidative stress in part through targeting of the potent proapoptotic factors, Bim and Bmf . In addition, overexpression of miR-133a in the skeletal muscle of mice did not result in any overt muscle defects . In our study, C2C12 cells cultured with EVs in growth medium did not exhibit a significant difference in survival compared with untreated control cells (data not shown). These findings indicate that miR-133a within EVs in the absence of cellular stresses may not affect muscle survival.
In addition, some previous reports indicated that caspase-9 is a possible direct target of miR-133a, and the inhibition of miR-133a increases caspase-9 and caspase-3 activity as well as the number of apoptotic cells in cardiomyocytes [53, 55–57]. Expression levels of caspase-3, caspase-9, and Bax expression levels have been shown to be significantly upregulated in the muscle of mdx mice . An imbalance between the production and degeneration of myocytes, exacerbated by increased apoptosis and decreased regenerative capacity leads to atrophy in the skeletal muscle of mdx mice . Moreover, it was reported that miR-133a is a direct target for apoptotic protease- activating factor 1and has a protective effect on apoptosis by repressing the expression of apoptotic genes . Moreover, miR-133a attenuates hypoxia-induced apoptosis by suppressing caspase-8 signals via its inhibition of the TAGLN2 gene in cardiomyocytes . It was recently demonstrated that miR-133a inhibits injury-induced cardiomyocyte apoptosis by targeting the DAPK2 gene . In our study, caspase-3 activity was decreased by miR-133a via EVs in C2C12 cells under conditions of cell stress. These findings indicate that modification of apoptosis by miR-133a might be a novel therapeutic strategy for DMD.
Expression of the inositol 1,4,5-triphoshate receptor II (IP3RII) calcium channel was constitutively suppressed by miR-133a . In cardiomyocytes, the inhibitory action of miR-133a maintains low basal IP3RII expression. The decline in miR-133a levels resulted in the upregulation of Ca2+ levels. In the present study, it was shown that the secretion of EVs from C2C12 cells may be modulated by intracellular Ca2+ concentrations. A chronic increase in Ca2+ concentrations in skeletal muscles fibers of DMD patients and mdx mice has been observed [63–65]. These reports suggest that the secretion of EVs may be regulated by increases in intracellular Ca2+ concentrations, which is induced by IP3RII targeting by miR-133a.
Treatment of mdx mice with GW4869 resulted in a significant decrease in myomiR levels in the serum compared with untreated mdx mice. In addition, myomiR levels in both EV-containing and EV-depleted supernatant fractions from the sera of GW4869-treated mdx mice were significantly lower than in untreated mdx mice. It was reported that the local injection of myomiRs or exosomes enhanced muscle regeneration and prevented fibrosis via the expression of myogenic factors in skeletal muscle of injured rat and mouse models [44, 66]. Exosomes extracted from differentiating human myoblasts include various gwoth factors, such as basic FGF, hepatocyte growth factor, insulin like growth factors-I, and vascular endothelial growth factor receptor, which are significantly upregulated in miR-133a-overexpressed adult mouse CPCs [43, 53]. Taking these findings together, the transfer of myomiRs via exosomes may play a role in muscle regeneration, although we cannot exclude the possibility of their beneficial effects on skeletal muscle repair via ceramide or its metabolites.
In summary, our study demonstrated that the release of myomiRs into the blood circulation was associated with the degeneration of skeletal muscle. The secretion of EVs may be regulated by ceramide metabolism by Smpd3 in C2C12 cells. Moreover, the transport of miR-133a via EVs into C2C12 cells increases cell survival under conditions of cellular stress. The inhibition of ceramide synthesis resulted in the suppression of EV secretion, and improved muscle dystrophy in mdx mice. Taken together, these findings suggest that EV-mediated myomiR delivery may have potential as a cell-free therapeutic strategy for DMD, by enabling intracellular communication.
S1 Fig. Levels of myomiRs in the sera of mdx mice.
(A) Levels of miR-1, miR-133a, and miR-206 in the sera of wt, mdx, and tg mice (7-weeks old, n = 3, 4, and 4, respectively). miR-21, miR-29, and sno202 are used as ubiquitous-expressed miRNAs. miR-302 is specifically expressed in embryonic stem cell. Data are represented as means + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001 for mdx vs wt or mdx vs tg.
S2 Fig. Contents of the EVs from serum.
(A) Western blots of exosomes isolated from 200 μL of serum from 5-week old mdx mice using antibodies of the exosome markers, CD63, CD9, caveolin-3, and MHC class II. HSP90, apoA-I, and calnexin was used as a positive or negative control for cell lysate from SHSY-5Y cells (cell lysate), exosome and exosome-depleted supernatant (sup). (B)Western blot of Lam2, exosome marker, using 50 μL of serum from 5-weeks old mdx or wt mice using antibody against the exosome marker Lamp2. Transferrin was used as a positive control. (C) EV content in the sera of wt, mdx, and tg mice. EVs were extracted from the sera of wt, mdx, and tg mice (7, 13, and 27-weeks old) by using Total Exosome Isolation kit. Ten μg/μL of EVs were serially diluted in PBS. One μL of EV solutions (10, 5, 2.5 1.25, 0.63, and 0.31 μg/μL) were subjected to dot blot analysis using anti-MHC class II and anti-CD63 antibodies.
S3 Fig. Levels of miRNAs in EVs.
(A) miR-16 level in the EVs separated by immunoprecipitation with anti-caveolin-3 (Cav3), anti-CD63, anti-CD81, anti-flotillin-1 (Flot1), or anti-MHC class II (MHC II) antibodies from the sera of DMD patients and controls (n = 5 and 4, respectively). (B) miR-1, miR-133a, or miR-206 levels in the EVs separated by immunoprecipitation with anti-caveolin-3, anti-CD63, anti-CD81, anti-flotillin-1, or anti-MHC class II antibodies from the sera of wt, mdx, and tg mice (7-weeks old, n = 3, 4, and 4, respectively). miR-16, miR-21, and miR-212 were used as ubiquitous-expressed miRNAs. miR-122a and miR-323 are specifically expressed in liver and brain, respectively. Data are represented as means + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001 for mdx vs wt or mdx vs tg.
S4 Fig. Measurement of the surface expression of caveolin-3, CD9, and CD81 on EVs extracted from the medium of C2C12 culture cells.
(A) EVs covalently bound by aldehyde/sulfate latex beads were mixed with antibodies against caveolin-3, CD9, and CD81, followed by the anti-rat IgG Alexa 488 secondary antibody, and then subjected to flow cytometry analysis. (left) Gating was performed to define area containing EVs, and percentages are indicated. (right) Representative flow cytometric histograms showing caveolin-3, CD9, and CD81-labeled exosome-bead complexes, with percentages indicated for each subpopulation. Staining without secondary antibody was used as a negative control. (B) Western blot analysis of cell lysate and exosomes from C2C12 myoblast cells using by Total Exosome Isolation Reagent with anti-CD63, anti-caveolin-3, anti-flotillin-1, anti-GAPDH, anti-HSP90, and anti-calnexin antibodies.
S5 Fig. Effects of calcium on the secretion of exosomes from C2C12 myoblasts.
(A-F) C2C12 cells (90% confluent) were incubated for 24 hr with GW4869 and monensin (A), GW4869 and A23187 (B), or GW4869 and caffeine (C), D-erythro-MAPP and BAPTA (D), D-erythro-MAPP and EGTA (E), or D-erythro-MAPP and 2-APB (F) in serum-depleted medium. (G-I) C2C12 cells (90% confluent) were incubated for 24 hr with S1P and EGTA (G), loperamide (H), and cyclopiazonic acid (I) in serum-depleted medium. (J) Schematic figure of the effects of calcium on exosome release. CRAC: calcium release-activated channels; Rab: Rab GTPase activating protein; SERCA: sarco/endoplasmic reticulum Ca2+-ATPase; RyR: ryanodine receptor; InsP3R: Inositol trisphosphate receptor. The amounts of released exosomes were quantified by measuring AChE activities. Data represent means + S.E. of absorbance at 405 nm. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
S6 Fig. Effect of EVs on C2C12 cell survival.
(A) C2C12 myoblasts (left) and myotubes (right) were differentiated for 3 days and then incubated for the indicted times in serum-depleted medium with low (0.7 μg), medium (2 μg), or high (6 μg) concentrations of EVs that were extracted from C2C12 culture medium. (B-D) C2C12 myoblasts were differentiated for 2 days in 2% serum-containing DMEM, followed by incubation with/without EVs (2 μg) extracted from mouse serum, in serum-free medium with or without 1.0 mM (+) or 2.0 mM (++) of methyl-ß-cyclodextrin (MßCD) for 48 hr (B), or 20 mg/mL of nocodazole (Nocod.) or 2 mM of Simvastatin (Simv.) for 48 hr (C), or 500 mM of U0126 for 24 hr (D). Data are represented as mean + S.D. for absorbance at 450 nm by CCK-8. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
S7 Fig. miR-1, miR-133a, and miR-206 levels within EVs extracted from the culture medium of C2C12 cells at different stages of differentiation.
C2C12 cells were cultured with growth medium until 90% confluency and then changed to differentiation medium for 1 to 6 days. miRNAs were isolated from EVs extracted from the media of C2C12 cells on the indicated days and miR-1, miR-133a, and miR-206 levels were measured by RT-quantitative PCR.
S8 Fig. myomiR levels within EVs extracted from C2C12 cells transfected with each myomiR.
miR-1, miR-133a, and miR-206 levels within EVs extracted from the medium of C2C12 cells transfected with miR-1, miR-133a, or miR-206, and their four possible combinations (miR-1/miR-133a, miR-1/miR-206, miR-133a/miR-206, and miR1/miR-133a/miR-206) were measured by RT-quantitative PCR. Levels are shown relative to that of the non-transfected cells, which was set to 1.
S9 Fig. Survival of myoblasts and myotubes upon incubation with EVs.
Myoblasts (A) and myotubes (B), differentiated for 4 days, were incubated with or without low (0.7 μg), medium (2 μg), or high (6 μg) concentrations of EVs extracted from the medium of C2C12 cells transfected with miR-1, miR-133a, or miR-206, or non-transfected (non-TF EVs) for 24 hrs in serum-depleted medium (A) or in the presence of H2O2 (10 mM) (B). Data represent mean + S.E. *: Pc < 0.05.
S10 Fig. Effect of miRNAs within EVs on C2C12 myotubes survival.
Myotubes were incubated in serum-depleted medium, with 0.8 μg (A), 2 μg (B) of EVs extracted from the medium of C2C12 cells transfected with miR-1, miR-133a, miR-206, or their four possible combinations (miR-1/miR-133a, miR-1/miR-206, miR-133a/miR-206, and miR1/miR-133a/miR-206) for the indicated times. Data are represented as mean + S.D. for absorbance at 450 nm by CCK-8. *: P < 0.05, ***: P < 0.001.
S11 Fig. myomiRs levels within EVs or EV-depleted supernatants.
miR-1, miR-133a, and miR-206 levels in EVs (A), or EV-depleted supernatants (B) from sera of untreated control mdx (mdx), GW4869-treated mdx for 5 days (GW4869-5d), GW4869-treated mdx for 10 days (GW4869-10d), and wt mice were measured by RT-quantitative PCR. Data represent mean + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
S12 Fig. Expression of utrophin in TA muscle.
TA muscle lysates of mdx mice treated with GW4869 for 10 days or untreated control mdx mice were subjected to western blotting to analyze utrophin expression. Gapdh (Glyceraldehyde 3-phosphate dehydrogenase) and tublin were used as loading controls.
S13 Fig. Secondary structure of the myomiRs, miR-1 (A), miR-133a (B), and miR-206 (C) based on ΔG values.
We thank Drs. Satoru Noguchi (National Center of Neurology and Psychiatry) and Naoki Ito (National Center of Neurology and Psychiatry) for kindly providing the C2C12 cells, Dr. Wataru Araki (National Center of Neurology and Psychiatry) for kindly providing the SHSY-5Y cells, and Mr. Satoru Masuda for technical supports with flow cytometry. This study was supported by Intramural Research Grant (25–5) for Neurological and Psychiatric Disorders of NCNP.
- Conceptualization: YM JT ST KH.
- Data curation: YM JT UR ST KH.
- Formal analysis: YM JT KH.
- Funding acquisition: ST KH.
- Investigation: YM JT ST KH.
- Methodology: YM JT ST KH.
- Project administration: ST KH.
- Resources: YM JT HK AI YO ST KH.
- Software: YM JT KH.
- Supervision: ST KH.
- Validation: YM JT UR ST KH.
- Visualization: YM JT KH.
- Writing – original draft: YM JT UR KH.
- Writing – review & editing: YM UR KH.
- 1. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev. 2002;12:349–361. pmid:12076680
- 2. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet. 2010; 55:379–388. pmid:20485447
- 3. Sultan A, Fayaz M. Prevalence of cardiomyopathy in Duchenne and Becker's muscular dystrophy. J Ayub Med Coll Abbottabad. 2008;20(2):7–13. pmid:19385447
- 4. Malm C, Sjödin TL, Sjöberg B, Lenkei R, Renström P, Lundberg I, et al. Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running. J Physiol. 2004;556:983–1000. pmid:14766942
- 5. Zatz M, Rapaport D, Vainzof M, Passos-Bueno MR, Bortolini ER, Pavanello Rde C, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J Neurol Sci. 1991;102(2):190–196. pmid:2072118
- 6. Lee S, Vasudevan S. Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol. 2013;768:97–126. pmid:23224967
- 7. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–471. pmid:18498749
- 8. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610. pmid:20661255
- 9. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–5008. pmid:21383194
- 10. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233. pmid:21609964
- 11. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–433. pmid:21423178
- 12. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248–7259. pmid:20615901
- 13. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. pmid:17486113
- 14. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–1476. pmid:19011622
- 15. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81. pmid:19996457
- 16. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A. 2010;107(14):6328–6333. pmid:20304794
- 17. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20(5):847–856. pmid:16453000
- 18. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 2007;110(7):2440–2448. pmid:17536014
- 19. Zhu H, Fan GC. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011;1:138–149. pmid:22059153
- 20. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet. 2012;3:56. pmid:22529849
- 21. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014;19(2):1568–1575. pmid:24473213
- 22. Cacchiarelli D, Legnini I, Martone J, Cazzella V, D'Amico A, Bertini E, et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med. 2011;3:258–265. pmid:21425469
- 23. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One. 2011;6:e18388. pmid:21479190
- 24. Li X, Li Y, Zhao L, Zhang D, Yao X, Zhang H, et al. Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients. Mol Ther Nucleic Acids. 22 2014; e177.
- 25. Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda S, et al. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014;19:452–458. pmid:25150707
- 26. Roberts TC, Blomberg KE, McClorey G, El Andaloussi S, Godfrey C, Betts C, et al. Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids. 2012;14:e39.
- 27. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 2010;12:341–351. pmid:20727829
- 28. Cazzella V, Martone J, Pinnarò C, Santini T, Twayana SS, Sthandier O, et al. Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther. 2012;20(11):2134–2142. pmid:22968481
- 29. Güller I, Russell AP. MicroRNAs in skeletal muscle: their role and regulation in development, disease and function. J Physiol. 2010;588:4075–4087. pmid:20724363
- 30. Matsuzaka Y, Hashido K. Roles of miR-1, miR-133a, and miR-206 in calcium, oxidative stress, and NO signaling involved in muscle diseases. RNA & Disease. 2015;2:e558.
- 31. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013;288:10849–59. pmid:23439645
- 32. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244–1247. pmid:18309083
- 33. Kubota S, Chiba M, Watanabe M, Sakamoto M, Watanabe N. Secretion of small/microRNAs including miR-638 into extracellular spaces by sphingomyelin phosphodiesterase 3. Oncol Rep. 2015;33(1):67–73. pmid:25394686
- 34. Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014;13:256. pmid:25428807
- 35. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MÁ, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2:282. pmid:21505438
- 36. Savina A, Fader CM, Damiani MT, Colombo MI. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005;6(2):131–143. pmid:15634213
- 37. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies. Neurology. 1978;28(5):439–446. pmid:76996
- 38. Kajimoto T, Okada T, Miya S, Zhang L, Nakamura S. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes. Nat Commun. 2013;4:2712. pmid:24231649
- 39. Savina A, Furlán M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003;278(22):20083–20090. pmid:12639953
- 40. Tamai K, Tanaka N, Nakano T, Kakazu E, Kondo Y, Inoue J, et al. Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. Biochem Biophys Res Commun. 2010;399(3):384–90. pmid:20673754
- 41. Ekström EJ, Bergenfelz C, von Bülow V, Serifler F, Carlemalm E, Jönsson G, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer. 2014;13:88. pmid:24766647
- 42. Forterre A, Jalabert A, Berger E, Baudet M, Chikh K, Errazuriz E, et al. Proteomic analysis of C2C12 myoblast and myotube exosome-like vesicles: a new paradigm for myoblast-myotube cross talk? PLoS One. 2014;9:e84153. pmid:24392111
- 43. Choi JS, Yoon HI, Lee KS, Choi YC, Yang SH, Kim IS, et al. Exosomes from differentiating human skeletal muscle cells trigger myogenesis of stem cells and provide biochemical cues for skeletal muscle regeneration. J Control Release. 2016;222:107–115. pmid:26699421
- 44. Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E, Svensson LM, et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem. 2013;288:17713–17724. pmid:23653359
- 45. Roberts TC, Godfrey C, McClorey G, Vader P, Briggs D, Gardiner C, et al. Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Res. 2013;41(20):9500–9513. pmid:23945935
- 46. Lane RE, Korbie D, Anderson W, Vaidyanathan R, Trau M. Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci Rep. 2015; 5:7639. pmid:25559219
- 47. Zeringer E, Li M, Barta T, Schageman J, Pedersen KW, Neurauter A, et al., Methods for the extraction and RNA profiling of exosomes. World J Methodol. 2013;3(1):11–18. pmid:25237619
- 48. Kim YK, Yeo J, Kim B, Ha M, Kim VN. Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell. 2012; 46(6):893–895. pmid:22749402
- 49. Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem. 2007;282:1384–1396. pmid:17085432
- 50. Shamseddine AA, Airola MV, Hannun YA. Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv Biol Regul. 2015;57:24–41. pmid:25465297
- 51. Levy M, Castillo SS, Goldkorn T. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem Biophys Res Commun. 2006;344:900–905. pmid:16631623
- 52. Clarke CJ, Hannun YA. Neutral sphingomyelinases and nSMase2: bridging the gaps. Biochim Biophys Acta. 2006;1758:1893–1901. pmid:16938269
- 53. Izarra A, Moscoso I, Levent E, Cañón S, Cerrada I, Díez-Juan A, et al. miR-133a enhances the protective capacity of cardiac progenitors cells after myocardial infarction. Stem Cell Reports. 2014;3:1029–1042. pmid:25465869
- 54. Deng Z, Chen JF, Wang DZ. Transgenic overexpression of miR-133a in skeletal muscle. BMC Musculoskelet Disord. 2011;12:115. pmid:21615921
- 55. Drawnel FM, Wachten D, Molkentin JD, Maillet M, Aronsen JM, Swift F, et al. Mutual antagonism between IP3RII and miRNA-133a regulates calcium signals and cardiac hypertrophy. J Cell Biol. 2012;199:783–798. pmid:23166348
- 56. He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci. 2011;18:22. pmid:21406115
- 57. Wang L, Li X, Zhou Y, Shi H, Xu C, He H, et al. Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:197–206. pmid:24190542
- 58. Honda A, Abe S, Hiroki E, Honda H, Iwanuma O, Yanagisawa N, et al. Activation of caspase 3, 9, 12, and Bax in masseter muscle of mdx mice during necrosis. J Muscle Res Cell Motil. 2007;28:243–247. pmid:17952618
- 59. Mouisel E, Vignaud A, Hourdé C, Butler-Browne G, Ferry A. Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice. Muscle Nerve. 2010;41:809–818. pmid:20151467
- 60. Dakhlallah D, Zhang J, Yu L, Marsh CB, Angelos MG, Khan M. MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart. J Cardiovasc Pharmacol. 2015;65(3):241–251. pmid:25658461
- 61. Li AY, Yang Q, Yang K. miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes. Mol Cell Biochem. 2015;400(1–2):173–181. pmid:25421410
- 62. Li S, Xiao FY, Shan PR, Su L, Chen DL, Ding JY, et al. Overexpression of microRNA-133a inhibits ischemia-reperfusion-induced cardiomyocyte apoptosis by targeting DAPK2. J Hum Genet. 2015;60(11):709–716. pmid:26334104
- 63. Mallouk N, Jacquemond V, Allard B. Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels. Proc Natl Acad Sci U S A. 2000;97(9):4950–4955. pmid:10781103
- 64. Robert V, Massimino ML, Tosello V, Marsault R, Cantini M, Sorrentino V, et al. Alteration in calcium handling at the subcellular level in mdx myotubes. J Biol Chem. 2001;276(7):4647–4651. pmid:11029464
- 65. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol. 2002;158(6):1089–1096. pmid:12235126
- 66. Nakasa T, Ishikawa M, Shi M, Shibuya H, Adachi N, Ochi M. Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J Cell Mol Med. 2010;14:2495–2505. pmid:19754672